| Allakos is a clinical stage biotechnology company. Co. is developing AK002, its wholly owned monoclonal antibody, for the treatment of various mast cell and eosinophil related diseases. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. Inappropriately activated mast cells and eosinophils have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. As such, AK002 has the potential to treat a number of severe diseases. We show 13 historical shares outstanding datapoints in our coverage of ALLK's shares outstanding history.|
Understanding the changing numbers of ALLK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALLK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALLK by allowing them to research ALLK shares outstanding history
as well as any other stock in our coverage universe.